AI Article Synopsis

Article Abstract

This study retrospectively evaluated the histopathological criteria commonly used in the literature on the diagnosis of hydatidiform mole, in correlation with the diagnosis rendered previously. The molar and non-molar cases seen in the first-trimester of pregnancy were separately reviewed by two pathologists. The correlation between the consensual histological diagnosis and the ploidy status was then evaluated. We retrospectively studied 89 specimens of abortus conception, including 35 complete hydatidiform moles (CHM), 12 partial hydatidiform moles (PHM), and 42 hydropic abortions (HA). The final histopathological diagnosis was compared with the results of DNA content detected by imaging analyzer (Samba 200), studying all cases of molar pregnancy and 4 cases of HA (initially diagnosed as molar pregnancies). In the consensus histological diagnosis, the cases were reclassified as follows: 30 CHM (initial diagnosis (ID): 27 CHM and 3 PHM), 12 PHM (ID: 6 PHM and 6 CHM), and one case with a persistent problem in differentiating PHM from HA and 46 HA (ID: 42 HA, 2 CHM, and 2 PHM). An agreement between the two pathologists was reached in 77 cases (K=0.72, 0.52, and 0.9, respectively, for CHM, PHM, and HA). The ploidy study demonstrated diploidy in 56.6% (17/30) of CHM and triploidy in 58.3% (7/12) of PHM. In the 4 cases of HA studied, 3 were diploid and 1 case was aneuploid. Our study demonstrated that several histopathological criteria could be used for the distinction between PHM, CHM, and HA. However, the study of DNA cannot be the technique of choice to distinguish between these entities. Some cases remain problematic since the morphological criteria are not easily reproducible. New sensitive techniques might resolve these dilemmas.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.prp.2009.05.013DOI Listing

Publication Analysis

Top Keywords

chm phm
12
phm chm
12
phm
9
molar non-molar
8
cases
8
histopathological criteria
8
histological diagnosis
8
hydatidiform moles
8
chm
8
phm phm
8

Similar Publications

Objectives: To audit outcomes of patients registered in the Queensland Trophoblast Centre (QTC) database who develop resistance to primary chemotherapy. To determine any risk factors that may predict first-line chemotherapy resistance in patients diagnosed with gestational trophoblastic neoplasia (GTN).

Methods: Patients within the QTC who were diagnosed with GTN between January 2012 and December 2020 were reviewed.

View Article and Find Full Text PDF

Gestational trophoblastic neoplasm: Patient outcomes and clinical pearls from a multidisciplinary referral center.

Gynecol Oncol

December 2024

Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, United States; Department of Medicine, Weill Cornell Medical College, New York, NY, United States.

Objectives: To describe clinical outcomes and pearls for patients with gestational trophoblastic neoplasm (GTN).

Methods: Patients with GTN treated at a referral center from 1/2006 to 12/2022 were included. Clinical characteristics, World Health Organization risk score (low-risk 0-6, high-risk ≥7), and treatments/outcomes were evaluated using summary statistics, stratified by initial treatment at a referral center versus locally.

View Article and Find Full Text PDF
Article Synopsis
  • The study utilized chromogenic in situ hybridization and immunohistochemistry to distinguish between partial hydatidiform mole (PHM), complete hydatidiform mole (CHM), and non-molar hydropic abortion (HA) in products of conception (POCs).
  • A retrospective analysis of 44 POCs revealed a high accuracy rate, with Kappa agreement at 95.4%, effective in diagnosing the conditions and differentiating between triploid and diploid specimens.
  • The findings suggest these methods could serve as reliable surrogate markers for chromosomal ploidy, prompting future research on fresh specimens and comparing results with other diagnostic techniques like flow cytometry and fluorescence in situ hybridization.
View Article and Find Full Text PDF

Comprehensive Proteomic Analysis Reveals Distinct Features and a Diagnostic Biomarker Panel for Early Pregnancy Loss in Histological Subtypes.

Mol Cell Proteomics

November 2024

Department of Gynecology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou City, Zhejiang Province, PR China. Electronic address:

Article Synopsis
  • Early pregnancy loss (EPL) includes various subtypes like hydropic abortion and hydatidiform moles, but diagnosing these conditions is difficult due to misdiagnosis and varying prognoses.
  • The study aimed to identify diagnostic biomarkers for EPL using proteomic analysis on samples from different miscarriage types and controls, resulting in the selection of 14 key proteins for identifying specific groups.
  • One protein, SPTB, was found to play a significant role in supporting cell functions connected to trophoblasts, which could lead to better diagnosis and treatment approaches for EPL.
View Article and Find Full Text PDF

Gestational Trophoblastic Disease: Complete versus Partial Hydatidiform Moles.

Diseases

July 2024

The Arkadi M. Rywlin M.D. Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Miami Beach, FL 33140, USA.

Hydatidiform moles, including both complete and partial moles, constitute a subset of gestational trophoblastic diseases characterized by abnormal fertilization resulting in villous hydrops and trophoblastic hyperplasia with or without embryonic development. This involves chromosomal abnormalities, where one or two sperms fertilize an empty oocyte (complete hydatidiform mole (CHM); mostly 46,XX) or two sperms fertilize one oocyte (partial hydatidiform mole (PHM); mostly 69,XXY). Notably, recurrent occurrences are associated with abnormal genomic imprinting of maternal effect genes such as (chromosome 19q13.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!